ABSTRACT

The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and development of the concept of TNFa inhibition. The a

chapter 1|16 pages

Theory and science of nebulizer use

History of nebulized aerosol delivery

chapter |1 pages

Drugs used in nebulizers

chapter |1 pages

Anticholinergics

chapter |9 pages

Pulmonary hypertension

chapter |10 pages

Microbiology of cystic fibrosis

chapter |7 pages

Nebulized antibiotics: practical issues

chapter |2 pages

Steroids and chromones

chapter 9|1 pages

Diagnostic uses of nebulizers

Chris Stenton and John Dennis

chapter 10|5 pages

Pediatric uses of nebulizers

Peter W Barry

chapter |1 pages

Maximum nebulizer output ~6 months Age

chapter |2 pages

~6 months Age

chapter |2 pages

Face masks, mouthpieces and nose clips

chapter |14 pages

Patient factors

chapter |15 pages

Nebulizer use in asthma and COPD

chapter |6 pages

Summary

chapter |17 pages

(f) insp 0 exp

chapter |12 pages

Providers

chapter |10 pages

* * *

chapter |6 pages

Conclusion

chapter 14|3 pages

Education and staff training

Karen Heslop and Louise Lannefors

chapter |1 pages

Patient factors

chapter |2 pages

Conclusion

chapter 15|4 pages

Summary and guidelines for use

Jacob Boe, John H Dennis and Ronan O’Driscoll